Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine

British Journal of Cancer

Volumn 82, Issue 8, 2000, Pages 1469-1473

  Friery, O P ^a   Gallagher, R ^a   Murray, M M ^a   Hughes, C M ^a   Galligan, E S ^a   McIntyre, I A ^a   Patterson, L H ^b   Hirst, D G ^a   McKeown, S R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Anti tumour effect; AQ4N; Cyclophosphamide; Tirapazamine

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BREAST CARCINOMA; DRUG CYTOTOXICITY; DRUG POTENTIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0034024671     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.1132     Document Type: Article

References (17)

1. Adams GE, Stratford IJ, Edwards HS, Bremner JCM and Cole S (1992) Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents SR4233 and the mitomycin C analogue EO9. Int J Radiat Oncol Biol Phys 22: 717-720
2. Brown JM and Lemmon MJ (1990) Potentiation by the hypoxic cytotoxin SR4233 of cell killing produced by fractionated irradiation of mouse tumours. Cancer Res 50: 7745-7749
3. Dorie MJ and Brown JM (1997) Modification of the anti-tumour activity of chemotherapy drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol 39: 361-266.
4. Holden SA, Teicher BA, Ara G, Herman TS and Coleman CN (1992) Enhancement of alkylating agent activity by SR4233 in the FSaIIC murine fibrosarcoma. J Natl Cancer Inst 84: 187-193
5. Johnson CA, Kilpatrick D, von Roemeling R, Langer C, Graham MA, Greenslade D, Kennedy G, Keenan E and O'Dwyer PJ (1997) Phase I trial of tirapazamine in combination with cisplatin in a single dose every three weeks in patients with solid tumours. Br J Cancer 73: 1480-1485
6. Kennedy KA (1987) Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Des 2: 181-194
7. Langmuir VK, Rooker JA, Osen M, Mendonca HL and Laderoute KR (1994) Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts. Cancer Res 54: 2845-2847
8. McAleer JJA, McKeown SR, MacManus MP, Lappin TRJ and Bridges JM (1992) Hypobaric hypoxia: a method for testing bioreductive drugs in vivo. Int J Radiat Oncol Biol Phys 23: 551-555
9. McKeown SR, Hejmadi MV, McIntyre IA, McAleer JJA and Patterson LH (1995) AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer 71: 76-81
10. McKeown SR, Friery OP, McIntyre IA, Hejmadi MV, Patterson LH and Hirst DG (1996) Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation. Br J Cancer 74: S39-S42
11. Moore JV (1988) The dynamics of tumour cords in an irradiated mouse mammary carcinoma with a large hypoxic cell component. Jpn J Cancer Res (Gann) 79: 236-243
12. Patterson LH (1993) Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metast Rev 12: 119-134
13. Siemann DW (1994) In vitro cytotoxicity and chemosensitizing activity of the dual function nitroimidazole RB6145. Int J Radiat Oncol Biol Phys 29: 301-306
14. Siemann DW (1996) The in situ tumour response to combinations of cyclophosphamide and tirapazamine. Br J Cancer 74: S65-S69
15. Smith PJ, Blunt NJ, Desnoyers R, Giles Y and Patterson LH (1996) DNA topoisomerase II dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides. Cancer Chemother Pharmacol 39: 455-461
16. Till JE and McCulloch EA (1961) A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 14: 213-222
17. Workman P and Stratford IJ (1993) The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metast Rev 12: 73-82